Clinical Trial Update: An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure [Phase 3]

View source ↗

Summary

An open-label, single-arm Phase 3 trial evaluating the hemodynamic effects and safety of Nesiritide in acute decompensated heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure
• Heart Failure

Drugs mentioned

• Nesiritide (Natrecor) (nesiritide)

Snippet

Sponsor: Xian-Janssen Pharmaceutical Ltd. | Conditions: Heart Decompensation, Congestive Heart Failure | Phase 3 | Status: COMPLETED